Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Marc LaForce

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Human Vaccines & Immunotherapeutics|September 18, 2025
Development of MenFive®, an affordable pentavalent meningococcal conjugate vaccine (ACYWX) for Africa and beyondMark R Alderson, Katie Regan, Lionel Martellet, et al.
Clinical and Vaccine Immunology : CVI|March 28, 2014
Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlersMargaret C Bash, Freyja Lynn, Brian Mocca, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2015
Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014Mamoudou H Djingarey, Fabien V K Diomandé, Rodrigue Barry, et al.
Vaccine|June 13, 2006
From genomics to surveillance, prevention and control: new challenges for the African meningitis beltJean-Michel Alonso, Eric Bertherat, William Perea, et al.
Vaccine|March 8, 2011
The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal diseaseLee H Harrison, Stephen I Pelton, Annelies Wilder-Smith, et al.
Vaccine|May 29, 2007
Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adultsNilima Kshirsagar, Naidu Mur, Urmila Thatte, et al.
Journal of Clinical Microbiology|October 5, 2012
Carriage of Neisseria lactamica in 1- to 29-year-old people in Burkina Faso: epidemiology and molecular characterizationPaul A Kristiansen, Fabien Diomandé, Rasmata Ouédraogo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2015
Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and LessonsGodwin C Enwere, Gandhali Paranjape, Prasad S Kulkarni, et al.
The Lancet. Infectious Diseases|July 24, 2012
Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance dataRyan T Novak, Jean Ludovic Kambou, Fabien Vk Diomandé, et al.
The Lancet. Infectious Diseases|August 19, 2018
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled studyWilbur H Chen, Kathleen M Neuzil, C Rebecca Boyce, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Human Vaccines & Immunotherapeutics|September 18, 2025
Development of MenFive®, an affordable pentavalent meningococcal conjugate vaccine (ACYWX) for Africa and beyondMark R Alderson, Katie Regan, Lionel Martellet, et al.
Clinical and Vaccine Immunology : CVI|March 28, 2014
Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlersMargaret C Bash, Freyja Lynn, Brian Mocca, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2015
Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014Mamoudou H Djingarey, Fabien V K Diomandé, Rodrigue Barry, et al.
Vaccine|June 13, 2006
From genomics to surveillance, prevention and control: new challenges for the African meningitis beltJean-Michel Alonso, Eric Bertherat, William Perea, et al.
Vaccine|March 8, 2011
The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal diseaseLee H Harrison, Stephen I Pelton, Annelies Wilder-Smith, et al.
Vaccine|May 29, 2007
Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adultsNilima Kshirsagar, Naidu Mur, Urmila Thatte, et al.
Journal of Clinical Microbiology|October 5, 2012
Carriage of Neisseria lactamica in 1- to 29-year-old people in Burkina Faso: epidemiology and molecular characterizationPaul A Kristiansen, Fabien Diomandé, Rasmata Ouédraogo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2015
Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and LessonsGodwin C Enwere, Gandhali Paranjape, Prasad S Kulkarni, et al.
The Lancet. Infectious Diseases|July 24, 2012
Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance dataRyan T Novak, Jean Ludovic Kambou, Fabien Vk Diomandé, et al.
The Lancet. Infectious Diseases|August 19, 2018
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled studyWilbur H Chen, Kathleen M Neuzil, C Rebecca Boyce, et al.
Pageof 5